The FDA approved the chimeric antigen receptor T-cell therapy axicabtagene ciloleucel, making it the second such treatment for blood cancers in the United States. The therapy is indicated for adults with certain non-Hodgkin lymphomas who have tried at least two other treatments.
http://ift.tt/2CMWQLz
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου